SynthesisFrontiers in gastroenterology (Lausanne, Switzerland)2022
A systematic review and meta-analysis of
Synthesis in Frontiers in gastroenterology (Lausanne, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Probiotics are widely used and prescribed to address a host of health issues. Despite evidence that different probiotic bacteria have differing therapeutic mechanisms of action, many probiotics are prescribed indiscriminately, with little research to support the use of specific formulations for a given ailment. Further investigation is required to assess the efficacy of one commonly prescribed probiotic formulation Methods: A systematic search of randomized placebo-controlled trials evaluating the effectiveness of combination Results: Analyses revealed the overall proportion of cases with diarrhea in the treatment group, 36 participants who had diarrhea out of 91 total, was only 3.5% lower than the overall proportion in the placebo group, 44 participants who had diarrhea out of 105 total.(P = 0.508), with our considering that the 3.5 lower percentage to be of little or no clinical importance. Conclusion: Existing literature suggests little or no clinical benefit of a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.